A5050042851- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Hormonal and reproductive studies
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Immunotherapy and Immune Responses
- PARP inhibition in cancer therapy
- Multiple Myeloma Research and Treatments
- Cancer Research and Treatments
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Bone health and treatments
- Cancer, Hypoxia, and Metabolism
- Fibroblast Growth Factor Research
- CAR-T cell therapy research
Yale University
2016-2025
Yale Cancer Center
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2004-2024
Smilow Cancer Hospital
2015-2024
National Cancer Institute
1999-2024
Yale New Haven Health System
2023-2024
National Institutes of Health
2024
Center for Cancer Research
2014-2024
Novartis (Switzerland)
2023
Bristol-Myers Squibb (Germany)
2023
Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine mitoxantrone prednisone metastatic, hormone-independent cancer.We randomly assigned 770 to one of two treatments, each given 21-day cycles: 280 mg three times daily on days 1 through 5, 60 per square meter body-surface area day 2, and dexamethasone divided doses before docetaxel, or 12 5 twice daily. The primary end...
Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options.In this open-label, international, phase 3 trial, we randomly assigned 542 patients cancer recurred or progressed to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1 [PD-1]) at dose of 200 mg every weeks the investigator's choice paclitaxel, docetaxel, vinflunine. The coprimary end...
Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall are limited by resistance.
PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes PSA will often antedate bone scan. Furthermore, many but not all investigators have observed an association between decline levels of 50% or greater survival. Since the majority phase II clinical trials for androgen-independent cancer (AIPC) used as marker, we believed it was important to agree on definitions values...
Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy safety of enzalutamide hormone-sensitive cancer (mHSPC).ARCHES (ClinicalTrials.gov identifier: NCT02677896) is multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume...
Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or ligand (PD-L1) inhibitor treatment.We conducted a global, open-label, phase 3 trial of enfortumab vedotin for the treatment patients locally metastatic who had previously received disease progression during PD-1 PD-L1 inhibitor. were randomly assigned in 1:1 ratio to receive (at dose 1.25 mg per kilogram body weight on days 1, 8, 15...
Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated platinum and anti-programmed death 1 ligand (PD-1/L1) therapy. Enfortumab vedotin antibody-drug conjugate that targets Nectin-4, which highly expressed in carcinoma.EV-201 a global, phase II, single-arm study of enfortumab 1.25 mg/kg (intravenously on days 1, 8, 15 every 28-day cycle) locally chemotherapy anti-PD-1/L1 The primary end...
Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% a median overall survival (OS) 7-8 months. Sacituzumab govitecan (SG) is TROP-2-directed antibody-drug conjugate an SN-38 payload has shown preliminary activity in mUC.
Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit pembrolizumab, programmed death 1 inhibitor, versus chemotherapy in UC that progressed on platinum-based chemotherapy. Here we report long-term safety and efficacy outcomes KEYNOTE-045.Adult histologically/cytologically confirmed whose disease after first-line, platinum-containing were enrolled. Patients...
Purpose We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, paclitaxel in advanced urothelial carcinoma patients prospectively evaluated human epidermal growth factor receptor-2 (Her-2/neu) overexpression rates. Patients Methods Advanced were screened for Her-2/neu overexpression. Eligibility therapy required by immunohistochemistry (IHC), gene amplification and/or elevated serum Her-2/neu, no prior...
Purpose This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen. Patients Methods Nine hundred fifty were randomly assigned (2:1) to receive (n = 635) 80 mg/m 2 on days 1 5 a 35-day cycle prednisone mg twice daily or placebo 315) daily. Primary end points...
Purpose To compare the safety and activity of DN-101, a new high-dose oral formulation calcitriol designed for cancer therapy, docetaxel with placebo docetaxel. Patients Methods progressive metastatic androgen-independent prostate adequate organ function received weekly 36 mg/m 2 intravenously 3 weeks 4-week cycle combined either 45 μg DN-101 or taken orally 1 day before The primary end point was prostate-specific antigen (PSA) response within 6 months enrollment, defined as 50% reduction...
Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysis data from three phase 3 trials was performed to immunologically characterize this therapy during course doses, and relate immunological responses overall survival (OS).Sipuleucel-T product...
PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers microtubule-disrupting agent, monomethyl auristatin E, to cells express Nectin-4. METHODS EV-101 is phase I dose escalation/expansion study enrolled patients with Nectin-4–expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on ≥ 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death...